

Date: 20th June 2014

SANCO-PHARMACEUTICALS-D5@ec.europa.eu

Subject: **Reply on topics discussed on 72nd Pharmaceutical Committee**

(...)

Agenda point: AOB 2. Update on external study on availability

Action: Submit comments on the study and, as applicable, an up-to-date list of products authorised under Article 126a (comments will be subsequently published with the study report)

Feedback: Slovenia currently holds no products authorized under the provision 126a of the Directive 2001/83/EC and uses other mechanisms to maintain the supply of all necessary products.

(...)